🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A great podcast worth listening to by Laureate Prof Clare Collins AO & Louise Baur talking about The Lancet Commission on Obesity & related topics.

Yeah, the #MAHA narrative about overuse of medications to treat pediatric obesity & statements about medications being used as a first-line treatment for 6 year olds are completely false.

Breaking news: Staff at the National Institutes of Health have issued a declaration calling on their director to depoliticize the agency and reverse spending cuts. scim.ag/3FN7HHK

You don’t get extra points for losing weight while being miserable. It’s okay to utilize medicines to help when indicated.

Obesity in childhood & adolescence increases the risk of multiple sclerosis later in life. nature.com/articles/s4136…

🔍 A new systematic review explores how well combined diet and physical activity interventions work for adolescents. The takeaway? Results are inconsistent and equity data is sorely lacking. 📚 Read more on our website: worldobesity.org/news/new-study… #FridayFindings

A must read. 👇🏻

The ADA stands with 135+ organizations who urge Congress to stop the elimination of @cdcgov’s National Center for Chronic Disease Prevention and Health Promotion. These cuts would devastate chronic disease prevention. Read the full letter: bit.ly/44aH6wF

No identifiable baseline predictors of response to Qsymia in #adolescents with #obesity, suggesting potential benefit for all patients. nature.com/articles/s4136…

And, essential to end obesity, which is a common denominator cause of countless other chronic diseases, including diabetes.

Dr. Bensignor is a leading expert on treating excess adiposity as the primary target in pediatric type 2 diabetes. Her approach is grounded in solid evidence. If you treat obesity, you treat diabetes.

People tell me that the ADA conference is now an obesity meeting. I’m returning after many years to find out firsthand if it’s true. The line between treatment of diabetes & obesity is pretty blurry these days. And, that’s a good thing.

I've had so many people in the industry tell me they now consider ADA annual conference as the premier obesity conference in the world. When is ADA rebranding to AOA? 😂

An in-depth report worth reading by Reuters chronicling the journeys of teens taking Wegovy. Link to the article & video below. This is how biomedical research makes lives better. reuters.com/investigates/s… reuters.com/video/watch/id…

From Eli Lilly and Company, Novo Nordisk, and a host of other companies, at #ADA2025 it feels a bit like a fire hose of new data on new #ObesityMedicines – including #orforglipron and #amycretin. The pipeline is full to overflowing. conscienhealth.org/2025/06/ada202…

Early & aggressive treatment of pediatric T2D with new obesity medications (e.g., semaglutide, tirzepatide) &/or bariatric surgery stands a good chance of meaningful altering these health trajectories. The risk/benefit of deploying these therapies is likely highly favorable.

More data are needed. But, GLP-1RAs are already indicated for obesity treatment in adolescents. So, they really should be first-line therapy for teens with T2D & obesity. Potential benefits likely greatly outweigh the risks.

At #ADA2025, #CagriSema prompts us to ask, how much #WeightLoss is enough and isn't it about time to focus on health gains? HT: @NovoNordisk conscienhealth.org/2025/06/ada202…

We’re entering an entirely new & exciting world in obesity medicine. Buckle up, it’s going to be fast & furious in the years to come! 🏎️💥

I am beyond proud to play my Dad card & claim that I am related to a member of Team USA, representing our country at the World Championships! Go Maya!! 🇺🇸